Background. Liver transplantation for nonresectable liver metastases from colorectal cancer was abandoned in 1994 on account of high recurrence rates. The aim of this study was to investigate whether the genetic detection of micrometastases in histologically negative lymph nodes of the primary colon cancer could be applied to select patients for liver transplantation. Methods. We analyzed 21 patients with colorectal cancer who had undergone liver transplantation between 1983 and 1994 for liver metastases. Eleven patients were histologically lymph node negative at the time of surgery; ten patients with lymph node metastases served as control group. DNA sequencing was used to screen tumor material for p53 and K-ras mutations. Mutant allele-specific amplification (MASA) was then used to search for micrometastases in DNA from regional lymph nodes of the primary colorectal cancer. Results. p53 and K-ras mutations were detected in 12 (57%) and 3 (14%) of 21 patients in the colorectal cancer, respectively. The mutations were confirmed in the corresponding liver metastases. Of 11 patients with histologically negative lymph nodes, nine were eligible for MASA due to presence of p53 or K-ras mutation. MASA revealed six of nine patients to be genetically positive for micrometastases. Three patients were both genetically and histologically negative. These three patients showed a significantly longer overall survival (Pϭ0.011) of 4, 5, and 20 years, respectively. Conclusions. We conclude that the genetic detection of micrometastases by MASA could be a powerful prognostic indicator for selecting patients with colorectal liver metastases who could benefit from liver transplantation.
A pproximately 50% of patients with colorectal cancer (CRC) develop liver metastases during the course of their disease, and 15-25% have liver metastases already at the time of surgery (1) . A further 20% of patients will develop metachronous metastases within the next 2 years (2). Surgical resection is the most efficient treatment for colorectal liver metastases (CRCLM), but only a limited number of patients are candidates for curative resection (3, 4) . In the remaining patients with nonresectable liver metastases, the prognosis is poor. Treatment is mainly symptomatic or palliative (5) .
Until 1994, liver transplantation (LTX) was an additional treatment option for these patients, but because of high recurrence rates, limited long-term survival and lack of organs, LTX for nonresectable liver metastases from colorectal cancer was abandoned in 1994 throughout the world (6 -9) .
At the Medical University of Vienna, 24 patients with colorectal liver metastases underwent liver transplantation between 1983 and 1994, representing one of the largest series with this indication. Very soon, transplantation was restricted to patients with histologically negative lymph nodes (pN0) of the primary colorectal cancer, which improved the results. Nevertheless, the program was stopped in 1994 due to organ shortage and the frequency of tumor relapses.
However, some patients experienced long-term survival, which encouraged us to develop the following hypothesis: If the results of LTX could be improved by restricting transplantation for CRCLM to patients with histologically negative lymph nodes of the primary, results could possibly be improved further by restricting LTX to patients who were also genetically negative for micrometastases.
As the lymph node stage is the strongest prognostic indicator for tumor relapse and overall survival in CRC, micrometastases might be significant for tumor relapse in patients after LTX as well (10, 11) .
Detection of lymph node metastases by p53 and K-ras MASA in histologically negative lymph nodes from colorectal cancer was first published by Hayashi et al. (12, 13) . MASA is an extremely sensitive polymerase chain reaction (PCR) technology which allows the molecular genetic detection of even single tumor cells (14) . Hayashi found the genetic detection of micrometastases to be a more precise prognostic marker than diagnosis by conventional histology (13) . In addition, the genetic detection of micrometastases in nonsmall-cell lung carcinoma patients using p53 and K-ras MASA proved to be more sensitive than immunohistochemical cytokeratin staining (15) .
The aim of this study was to investigate whether the absence of micrometastases in histologically negative lymph nodes of primary CRC could be used to select patients with liver metastases who would benefit from LTX.
MATERIALS AND METHODS

Patients
Tumor material from 21 patients with nonresectable liver metastases after colorectal cancer and who underwent liver transplantation between 1983 and 1994 was available for analysis. Eleven patients had shown no histologically detectable lymph node metastases at the time of surgery (pN0); ten patients with lymph node metastases (pN1) were used as control group. Clinicopathological characteristics of the 21 patients are shown in Table 1 . Chemotherapy was administered at the time of recurrence to a few patients only and was not given as an adjuvant treatment routinely after LTX.
For analysis, we used paraffin-embedded tissue from the primary CRC, the liver metastases and all regional lymph nodes available of the primary tumor. All tumors were reexamined conventionally by an experienced histopathologist (F.W.). Re-examination of the histologic sections of lymph nodes for the presence of lymph node metastases was based on rereview of slides. Follow-up ended in July 2003.
DNA Preparation From Paraffin-Embedded Tissue
Depending on the size of the tissue, 5-10 unstained sections of 5-m thickness were used for DNA extraction. Cancer tissue was harvested from paraffin-embedded slides and subjected to 100 l xylene and 100 l absolute ethanol. The mixture was centrifuged at 12,000 rpm for 10 min, and the supernatant was discarded. After drying at 55°C, the tissue was resuspended in 250 l of 50 mM TRIS-HCL (pH 8.0) and digested with 50 g proteinase K (Roche Diagnostics, Mannheim, Germany) for 2 h at 65°C. The enzyme was inactivated by incubation at 95°C for 8 min.
Detection of Genetic Alterations of Primary
Tumors and Liver Metastases
PCR Amplification
The obtained DNA was usually diluted 1:10. Exons 2 to 10 of the p53 gene were amplified by seven different PCRs using synthetic oligonucleotide primers of 20 bases in length, placed in the adjacent intron regions of exons 2-3, 4, 5, 6, 7, 8-9 and 10, as listed previously (16) . Codons 12 and 13 of K-ras were examined by amplification of exon 1 (17) . Amplification was performed in a total volume of 50 l for 45 cycles using 2 l of diluted DNA, 20 pmol of each primer and 1.25 U of AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA) as previously described (18) . For quality and quantity assessment, PCR products were analyzed on precast 6% acrylamide/bisacrylamide gels (Novex, San Diego, CA). 
As reference size standard we used the Msp I digest of pBR322-DNA (Clontech Lab, Palo Alto, CA).
Enzymatic Treatment of PCR Products
Before sequencing, PCR products were cleaned from single-stranded DNA residues such as primers and excess dNTPs; 2 l of each sample were incubated at 37°C for 1 hr with 5 U exonuclease I (Amersham Pharmacia Biotech AB, Uppsala, Sweden) and 5 U of shrimp alkaline phosphatase (Amersham Pharmacia Biotech AB, Uppsala, Sweden) in a total volume of 20 l. By means of the following incubation at 72°C for 15 min, the enzymes were inactivated. Afterwards the purified PCR products were diluted by adding 15 l of Aqua Bidest.
Sequencing
For direct sequencing, the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) was used. The amplification was performed in a total volume of 5 l using 1.5 l of purified PCR product, 1 pmol of primer and 1 l of Terminator Ready Reaction Mix. We used the forward primers for exons 5, 7, 8 -9 and the reverse strand primers for exons 2-3, 4, 6, and 10 of p53. Codons 12 and 13 of K-ras were sequenced with the antisense primer of exon 1. For T1 Thermocycler (Biometra, Goettingen, Germany), the following thermal profiles were used: 10 s denaturation at 96°C, 5 s annealing at 50°C and 3 min extension at 60°C for 25 cycles. Sequence reaction was then purified by Centri-Sep Spin Columns (Applied Biosystems, Foster City, CA). Sequence analysis was performed with ABI Prism 310 Genetic Analyzer. Each identified mutation was confirmed in a separate experiment.
Detection of Micrometastases: MASA
To test DNA from regional lymph nodes for the presence of tumor-specific genetic alterations which would prove the presence of histologically undetected tumor cells, we synthesized MASA primers corresponding to each tumor-specific p53 or K-ras variant identified in the primary tumors. First we preamplified lymph node DNA from the very exon of p53 (or K-ras) where the mutation was located in the primary colon cancer and the liver metastasis. Then MASA was performed in a total volume of 50 l for 45 cycles using 2 l of purified PCR product, 20 pmol of each primer and 1.25 U of AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA). PCR products (10 l) were run on electrophoresis on precast 6% acrylamide/bisacrylamide gels (Novex, San Diego, CA) and visualized by ethidium bromide. All specimens were analyzed at least twice to confirm the results. As negative control we used DNA from patients with wild type p53 or K-ras.
Statistical Analysis
Data were analyzed using the SPSS for Windows Release 10.0 software package (SPSS Inc., Chicago, IL). Survival, measured from the date of liver transplantation to the time of the last follow-up or death and recurrence, calculated from the time of LTX to the time of relapse were related to the presence of micrometastases. Overall survival (OS) and recurrence-free survival (RFS) was calculated using the KaplanMeier estimates. The comparison of the survival curves for patients with and without micrometastases was performed by log-rank test. Data were considered significant at a level of PϽ0.05.
RESULTS
Direct DNA sequencing of the primary CRC of 21 patients showed the presence of a p53 mutation in 12 (57%) patients and a K-ras mutation in 3 (14%) patients. Mutations in both genes were found in two cases. By sequencing the corresponding liver metastases of the 21 patients, we found the same mutations as observed in the primary tumors (Fig.  1) . We found only one case of p53 mutation in a liver metastasis which was not present in the colorectal cancer.
Mutations of p53 and K-ras found in our patients are characterized in Table 2 .
Eleven patients were found to be histologically negative for lymph node metastases (pN0) at the time of colorectal surgery. Eight (73%) of them had a p53 mutation in the primary tumor and the liver metastasis, two had an additional K-ras mutation. One patient had a K-ras mutation in the CRC which was conserved in the liver metastasis, and an additional p53 mutation in the liver metastasis only.
Ten patients were histologically positive for lymph node metastasis (pN1) at the time of colorectal surgery. Four (40%) of them had a mutation in the p53 gene, and no patient showed a mutation in the K-ras gene.
To prove the presence or absence of tumor cells in the regional lymph nodes, we synthesized PCR primers corresponding to the tumor-specific DNA alterations for each patient. These primers guarantee that exclusively DNA containing the individual mutation will be amplified during PCR reaction. With these specific primers we performed MASA PCR with DNA from regional lymph nodes of the primary.
Nine of eleven histologically lymph node-negative patients were eligible for MASA due to presence of a tumorspecific genetic marker (p53 or K-ras mutation). We used p53 MASA primers for eight patients and K-ras MASA primers for one patient. In six of nine patients, tumor-specific sequences could be amplified from lymph node DNA, proving the presence of tumor cells in the regional lymph nodes although the nodes had been diagnosed as tumor-free by conventional histology (Fig. 2A) . Three patients had histologically and genetically negative lymph nodes (Fig. 2B) .
In the control group (pN1), four patients were eligible due to presence of a tumor-specific (p53) mutation. MASA technique confirmed the existence of tumor cells in the histologically positive lymph nodes in all four patients of the control group. Figure 3 shows the Kaplan Meier survival analysis for recurrence-free and overall survival of patients with histologically negative lymph nodes. Patients with and without genetically diagnosed lymph node metastases are compared. Patients with genetically diagnosed lymph node micrometastases showed a significantly poorer relapse-free and overall survival of 8.6 months and 28 months median, respectively. In patients without micrometastases, the relapse-free and overall survival was 100 months and 118 months median, respectively ( Table 3) .
The Kaplan Mayer survival analysis showed a significant correlation between the absence of micrometastases and an improved recurrence-free (Pϭ0.036) and overall (Pϭ0.011) survival.
DISCUSSION
LTX for nonresectable liver metastases from colorectal cancer is currently not recommended as a treatment option due to high recurrence rates and limited organ availability. However, in our historic series of 24 patients with LTX for CRCLM, a small number of patients showed impressing overall and recurrence-free survival. This encouraged us to search for a selection criterion which may allow offering LTX to a well-selected group of patients.
Our results suggest that the genetic detection of lymph node micrometastases might be a valuable method to select patients with CRCLM for liver transplantation.
Based on the observation that relapse rates after LTX for CRCLM could be improved by excluding patients with positive lymph nodes (Dukes C) from LTX, we suggest that lymph node micrometastases might be involved in tumor recurrence in Dukes A and Dukes B patients after LTX.
Cancer is a disease of the genes. Mutations in the p53 tumor suppressor gene or the K-ras oncogene are frequently present in colorectal cancers (19) . Being conserved in metas- tases, these genetic mutations can serve as tumor-specific markers. In our study we sequenced primary colorectal tumors and the matching liver metastases of 21 patients: in accordance with previously reported data, we found the mutations of the p53 and K-ras genes to be conserved in metastases (20 -23) . In one patient, a p53 mutation was found in the liver metastasis which was not present in the primary tumor. In colon cancer, p53 mutations have been reported to occur at the time of tumor progression from high grade dysplasia to cancer (19) . It also has been observed that tumors containing p53 mutation more often develop liver metastases (24, 25) . However, CRCLM rarely contain p53 mutations if the primary tumors do not. For our p53 mutational analysis, the whole coding sequence and the adjacent intron regions of the p53 gene were divided into seven parts which are amplified separately. Due to the limited length of DNA which is needed to be amplified, we generally do not face amplification problems due to DNA degradation in specimens even if they have been stored for 20 years or more. Mutational artefacts, which have been reported to arise as a result of tissue preservation in paraffin (26) , can almost be ruled out for our study: An identical mutation which is present in three separate tissues (primary, lymph node, liver metastases) harvested at different times is highly unlikely to be derived from artefacts.
MASA PCR is based on the amplification of tumorspecific, mutated DNA, which is used as a genetic marker. Being based on PCR technology, MASA has an extreme high specificity and sensitivity, allowing the detection of approximately one tumor cell in 1000 normal cells. Yamamoto et al. argued that the super-sensitivity of genetic methods in micrometastases detection may be associated with an increased rate (28) . In summary, the detection of tumor DNA seems to be related to worse prognosis.
In our study, we found a significant correlation between genetically detected micrometastases and the recurrence-free and the overall survival, respectively. One of three patients (#25) with genetically negative lymph nodes has been alive for more than 20 years and showed no recurrence at the last follow up.
The other two patients suffered from relapse and died from cancer, in spite of having genetically negative lymph nodes: One patient (#6) underwent LTX five months before the resection of the primary colon cancer because the liver metastasis was initially misinterpreted as primary liver cancer; the other patient (#17) underwent resection for synchronous liver metastases, a further resection for liver metastases was carried out after a 2-year interval. After further 2 years, liver metastases occurred again, and the patient underwent transplantation 6 months after having received chemotherapy while on the waiting list. In this patient, a relapse occurred in the lung 26 months after LTX, which might indicate a hematogenic way of tumor spread.
Nevertheless, these two patients showed a significantly longer overall survival time (51 and 62 months, respectively), compared to that of the six patients with genetically positive but histologically negative lymph nodes (median OS 28 months).
One limiting factor of the MASA PCR to distinguish tumor cells in lymph nodes from colorectal cancer is that to date no genetic mutation is known to occur consistently in the majority of colorectal neoplasms. However, mutations of the p53 and K-ras genes are the most common genetic alterations, occuring in 60% (25) and 40% (29) of colorectal tumors, respectively.
Other genes known to be mutated in CRC, such as the APC and ␤-catenin gene (30) or p16 promoter hypermethylation (31) could be possibly addressed to analyze patients even without p53 and K-ras mutations, although this would enormously increase the laboratory effort.
Due to tumor recurrence and disappointing long-term results, LTX for nonresectable liver metastases from colorectal cancer was considered a waste of organs, in the light of donor organ shortage, and discontinued in 1994. Today, liver surgery is performed at a higher standard than years ago, and the trend is to increase the rate of surgical resections of liver metastases, to date the only curative approach. Furthermore, liver resection may be achieved in primarily unresectable patients by means of downstaging with the help of effective neoadjuvant chemotherapy (5, 32) .
Therefore, fewer patients with nonresectable liver metastases and histologically negative lymph nodes of the primary will present themselves as candidates for LTX.
In summary, the effort of genetic micrometastases detection for such an exclusive group of patients appears to be quite reasonable in relation to the logistic and economic efforts of LTX. With the MASA technique described in this study, results can be obtained within a few weeks. It furthermore appears reasonable to spare patients from a high risk operation, potentially leading to early relapse due to immunosuppression and to give those patients who potentially benefit from LTX the chance for an organ replacement.
Based on our results, we recommend undertaking an effort to provide liver transplantation to strictly selected patients with CRCLM. The detection of micrometastases in histologically negative lymph nodes using MASA technology could serve as a valuable tool for selection of patients.
